Browse studies

Find your next paid study

3,219 recruiting studies matching your filters

A Phase 1, Open-label, Multicenter Clinical Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Cancer Activity of PQ203 in Patients With Advanced Solid Tumor Malignancies

The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breas…

Triple Negative Breast Cancer (TNBC)Advanced Solid Tumors Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

ProteinQure Inc.NCT07190469

Multi-Site Feasibility Testing of the Ventricular Assist Device Anticipatory Guidance Tool

There are a variety of educational documents available to help in a participant's decision for VAD implant, however there is little information available to po…

Ventricular Assist DeviceAdvanced Heart FailureAnticipatory Guidance

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Bryan HeartNCT06823583

Phase 2

A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) With Radiographic Occult Molecular Residual Disease Treated With Botensilimab (AGEN1181; Bot) Plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)

This phase II trial tests the effect of the botensilimab in combination with balstilimab in treating patients with stage II/III colorectal adenocarcinoma with …

Colorectal AdenocarcinomaStage II Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07551596

Phase 2

A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy …

Advanced High-Grade Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancers

Estimated

~$75 – $3,000

Actual pay is set by the research site.

AbbVieNCT06682988

Measuring Surgical Recovery After Radical Cystectomy

The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the co…

Bladder Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT03193970

Phase 1

A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy o…

Advanced Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

TiumBio Co., Ltd.NCT05204862

Phase 2

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with…

Non-muscle Invasive Bladder Cancer

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Protara TherapeuticsNCT05951179

PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is toler…

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

Estimated

~$10 – $1,125

Actual pay is set by the research site.

BayerNCT04142437

Phase 1

Effects of Stimulant Medications in PTSD

While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of …

AdderallPTSDPost Traumatic Stress Disorder

Estimated

~$500 – $7,500

Actual pay is set by the research site.

University of ChicagoNCT07664631

Observational

Project HOPEFUL (Helping Older PErsons Find Useful Links): Replicating a Partially Nested Randomized Control Trial With Implementation Science

This PN-RCT replicates and evaluates an 8-week warm calling treatment (i.e. caring contacts) delivered to older adults receiving home and community-based servi…

Older Adults (50-90 Years)Mental HealthDepression and Suicide Ideation+4 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of FloridaNCT07475039

Phase 2

Intravesical Nadofaragene Firadenovec With Neoadjuvant Chemotherapy and Durvalumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)

This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with gemcitabine, cisplatin and durvalumab before (neoadjuvant) ra…

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of WashingtonNCT07332351

Phase 4

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

Head and Neck Squamous Cell Carcinoma

Estimated

~$25 – $1,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT06162377